TransMedics Raises 2026 Revenue Guidance Following Record Third Quarter Results
TransMedics (TMDX) reported record third-quarter revenue of $203 million, representing a 41% year-over-year increase. Despite a seasonal decline in U.S. donor organ availability, the company achieved its highest quarterly revenue and case volume to date, driven by increasing customer adoption of its Organ Care System (OCS) technology. Looking forward, management raised full-year 2026 revenue guidance to a range of $764 million to $774 million. The company is focused on expanding its market reach through the ENHANCE heart and DENOVO lung clinical programs, which aim to capture thousands of additional annual procedures. Additionally, TransMedics continues development on its kidney preservation system, with human clinical testing slated for late 2027.
Tickers: $TMDX
Topics: medical technology organ preservation quarterly earnings revenue guidance